Stephen C Pflugfelder1, Michael E Stern. 1. Ocular Surface Center, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA. stevenp@bcm.tmc.edu
Abstract
PURPOSE OF REVIEW: To review recent advances in pathogenesis and treatment of conjunctival inflammatory disorders. RECENT FINDINGS: The conjunctiva becomes inflamed in a number of conditions, including allergy, atopy, dry eye, mucus membrane pemphigoid, Stevens-Johnson syndrome and surgical manipulation. Basic and clinical studies have identified a number of inflammatory mediators as potential therapeutic targets in these conditions. Additionally, new therapeutic agents and enhanced delivery systems have been evaluated. SUMMARY: Increased understanding of the key mediators of conjunctival inflammation coupled with improved drug delivery methods are leading to more effective therapy for conjunctival inflammatory disorders.
PURPOSE OF REVIEW: To review recent advances in pathogenesis and treatment of conjunctival inflammatory disorders. RECENT FINDINGS: The conjunctiva becomes inflamed in a number of conditions, including allergy, atopy, dry eye, mucus membrane pemphigoid, Stevens-Johnson syndrome and surgical manipulation. Basic and clinical studies have identified a number of inflammatory mediators as potential therapeutic targets in these conditions. Additionally, new therapeutic agents and enhanced delivery systems have been evaluated. SUMMARY: Increased understanding of the key mediators of conjunctival inflammation coupled with improved drug delivery methods are leading to more effective therapy for conjunctival inflammatory disorders.